ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved …
Dec 7, 2022 · ENHERTU® (fam-trastuzumab deruxtecan-nxki) achieved statistically significant overall survival, reducing the risk of death by 36% vs. trastuzumab emtansine (T-DM1) in …
Enhertu achieved statistically significant overall survival, reducing ...
Dec 7, 2022 · DESTINY-Breast03 is a global, head-to-head, randomised, open-label, registrational Phase III trial evaluating the efficacy and safety of Enhertu (5.4mg/kg) versus T …
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 ...
Nov 4, 2020 · DESTINY-Breast05 is a phase 3, multicenter, randomized, open-label, active-controlled study of ENHERTU versus T-DM1 in patients with high-risk HER2 positive primary …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) additional analyses further ...
Dec 9, 2021 · New results from the DESTINY-Breast03 Phase III trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a higher progression-free survival (PFS) …
Efficacy data | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
In DESTINY-Breast03, a head-to-head study vs T-DM1, ENHERTU delivered 82.1% confirmed ORR 5. The DESTINY-Breast03 study protocol did not power ORR—a secondary …
Greater Benefit With Trastuzumab Deruxtecan Vs T-DM1 …
Sep 19, 2021 · Enhertu significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive …
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
Apr 5, 2024 · DESTINY-Breast01 is a global, single-arm, open-label, two-part multicenter Phase II trial evaluating the safety and efficacy of ENHERTU in patients with HER2-positive …
Enhertu reduced the risk of disease progression or death by 72
Sep 18, 2021 · DESTINY-Breast03 is a global head-to-head, randomised, open-label, registrational Phase III trial evaluating the safety and efficacy of Enhertu (5.4mg/kg) versus T …
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast …
Mar 23, 2022 · Trastuzumab deruxtecan (also known as T-DXd and DS-8201) is an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to …
Comparing Antibody-Drug Conjugates for Metastatic Breast Cancer
Mar 22, 2022 · The Food and Drug Administration has approved two antibody-drug conjugates for metastatic HER2-positive breast cancer that progresses after first-line treatment: Kadcyla (ado …